Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO

Core Insights - Illumina is presenting research at the ASCO Annual Meeting aimed at advancing genomic testing as a standard of care in oncology [2][3] - The studies focus on the clinical utility of comprehensive genomic profiling (CGP), overcoming market access barriers, and the development of molecular residual disease (MRD) assays [1][8] Group 1: Research Collaborations - Illumina and Labcorp have five abstracts accepted at ASCO, focusing on the clinical impact of comprehensive biomarker testing [3] - A notable study involves a machine learning algorithm for detecting tumor microsatellite instability (MSI) in colorectal cancer, analyzing samples from 1,838 patients [3][4] Group 2: Comprehensive Genomic Profiling (CGP) - Illumina is validating the clinical utility of CGP over single-gene testing (SGT), with a real-world analysis showing that only 1.2% of stage IV non-small-cell lung cancer (NSCLC) patients received results for all nine guideline-recommended biomarkers through SGT, compared to 71.7% for CGP [5][6] - This evidence supports the transition to comprehensive next-generation sequencing as the standard of care for NSCLC [6][7] Group 3: Molecular Residual Disease (MRD) Assay - Illumina will present an evaluation of its MRD assay, highlighting its fast turnaround time, low input requirements, and high sensitivity and specificity compared to existing market options [8] - Collaborations with pharmaceutical companies are underway to innovate on the MRD research assay, which is based on a whole-genome approach [8]